Efficacy and safety of molnupiravir for the treatment of non-hospitalized adults with mild COVID-19: a randomized, open-label, parallel-group phase 3 trial

SK Tippabhotla, DS Lahiri, C Kandi - papers.ssrn.com
Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …
被引用次数：24 相关文章

Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial

SK Tippabhotla, DS Lahiri, D RR, C Kandi, V NP - 2022 - europepmc.org
Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …